Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 24, 2026
Why Is Similarweb (SMWB) Stock Down -12.47% Today?

Why Is Similarweb (SMWB) Stock Down -12.47% Today?

Key Takeaways

  • Similarweb (SMWB) shares fell 12.47% in Thursday's session, dropping to $7.51 from a prior close of $8.58.
  • The primary catalyst was the announcement that Michael Akkerman will succeed founder Or Offer as Chief Executive Officer, effective November 2, 2026.
  • Secondary pressure came from a series of insider share sales by the departing CEO disclosed in recent SEC filings.
  • A broader risk-off tape—with major indices lower and digital analytics peers soft—amplified the company-specific selling.
  • Traders are now watching the leadership transition, upcoming quarterly results, and whether the stock holds key technical support.

Opening Summary

Similarweb Ltd. (SMWB), a digital intelligence and data analytics company that provides web traffic and digital-market insights, saw its shares drop sharply on Thursday. The stock fell 12.47% to $7.51, down from the prior session's closing price of $8.58. The decline followed the company's announcement of a leadership change at the top, as investors weighed the departure of a long-tenured founder-CEO alongside a wave of insider selling and a weak broader market backdrop.

CEO Transition Weighs on Sentiment

The immediate trigger for the move was Similarweb's announcement that Michael Akkerman will become Chief Executive Officer effective November 2, 2026. Akkerman succeeds founder and CEO Or Offer, who is stepping down after nearly two decades leading the company—a departure first signaled back in May 2026. Akkerman brings roughly two decades of leadership experience across digital advertising, data, and technology, most recently as Chief Business Officer of Digital Turbine (APPS), with earlier roles at data.ai, Cardlytics (CDLX), Uber (UBER), and Pinterest (PINS).

Although the company emphasized that its strategy, operations, and financial outlook remain unchanged, the market reaction underscored investor caution about founder-level transitions. The departure of a founder who has led the business since inception naturally raises questions about execution, priorities, and the pace of growth during a pivotal moment in the company's push into AI-powered data products. Shares initially nudged higher in pre-market trading before sentiment turned decisively negative as the session progressed.

Insider Selling Adds Pressure

Compounding the leadership announcement, recent SEC Form 4 filings showed that departing CEO Or Offer sold tens of thousands of shares in the days leading up to the news, with transactions executed at prices in the $8.38–$8.54 range under a pre-arranged Rule 10b5-1 trading plan. While such planned sales are common and do not necessarily signal a shift in fundamentals, the combination of a high-profile founder exit and concurrent insider disposals weighed on investor confidence, reinforcing the session's downward momentum.

Market Context and Trading Activity

The stock's slide also reflected a broader risk-off environment. Major U.S. indices were lower during the session, with the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all posting declines. That backdrop is particularly challenging for small- and mid-cap technology names, which tend to be more sensitive to shifts in risk appetite. Similarweb's digital analytics peers also traded lower, indicating that sector-wide softness amplified the company-specific headwinds.

Trading activity was elevated relative to the stock's typical volume, with heavy turnover as investors reassessed the risk profile of the transition. The selloff pushed shares back toward the lower end of their recent trading range after a sharp run-up from a 52-week low of $2.22, underscoring how quickly positive momentum can unwind when a catalyst is perceived as negative.

What Comes Next for SMWB

Looking ahead, investors will focus on the handoff between Offer and Akkerman and any signals about strategic direction as the new CEO takes the helm from New York in early November. The company's next quarterly earnings report will be closely watched for evidence that its AI-powered data products and go-to-market execution continue to scale. Analyst expectations remain broadly constructive on the name, but the leadership transition introduces execution risk that could keep the stock volatile in the near term. Broader market conditions and sector sentiment around digital analytics and AI software will also play a role in shaping the stock's path.

Trending AI Robots

For traders seeking a data-driven edge across shifting market conditions, Tickeron's Trending AI Robots page showcases a curated selection of its strongest-performing AI trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only those delivering standout results under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches to explore. Discover which AI strategies are leading the market today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SMWB

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Aroon Indicator for SMWB shows an upward move is likely

SMWB's Aroon Indicator triggered a bullish signal on September 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 193 similar instances where the Aroon Indicator showed a similar pattern. In 165 of the 193 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 65 cases where SMWB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on SMWB as a result. In 65 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

Following a +1.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMWB advanced for three days, in 208 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for SMWB moved out of overbought territory on September 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 30 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Moving Average Convergence Divergence Histogram (MACD) for SMWB turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMWB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SMWB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.223) is normal, around the industry mean (51.913). P/E Ratio (0.000) is within average values for comparable stocks, (83.282). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.150). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.449) is also within normal values, averaging (70.180).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMWB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Salesforce (NYSE:CRM), Shopify Inc (NASDAQ:SHOP), ServiceNow Inc. (NYSE:NOW), Uber Technologies (NYSE:UBER), Adobe (NASDAQ:ADBE), Datadog (NASDAQ:DDOG), Intuit (NASDAQ:INTU), Atlassian Corp (NASDAQ:TEAM), Workday (NASDAQ:WDAY), Autodesk (NASDAQ:ADSK).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 10.21B. The market cap for tickers in the group ranges from 39 to 246.36B. SAPGF holds the highest valuation in this group at 246.36B. The lowest valued company is STIXF at 39.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was -1%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 10%. SECZ experienced the highest price growth at 85%, while FRGT experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 76
Price Growth Rating: 58
SMR Rating: 77
Profit Risk Rating: 94
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
SMWB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Industry
N/A
Address
33 Yitzhak Rabin Road
Phone
+972 35447782
Employees
1000
Web
https://www.similarweb.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.